- Home
- JANX vs BHVN Comparison
JANX vs BHVN Comparison
Compare JANX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- BHVN
- Stock Information
- Founded
- JANX 2017
- BHVN 2013
- Country
- JANX United States
- BHVN United States
- Employees
- JANX N/A
- BHVN 256
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- BHVN Health Care
- Exchange
- JANX Nasdaq
- BHVN Nasdaq
- Market Cap
- JANX 1.7B
- BHVN 1.1B
- IPO Year
- JANX 2021
- BHVN 2017
- Fundamental
- Price
- JANX $29.41
- BHVN $8.29
- Analyst Decision
- JANX Strong Buy
- BHVN Strong Buy
- Analyst Count
- JANX 10
- BHVN 16
- Target Price
- JANX $77.40
- BHVN $37.07
- AVG Volume (30 Days)
- JANX 1.1M
- BHVN 5.5M
- Earning Date
- JANX 11-06-2025
- BHVN 11-10-2025
- Dividend Yield
- JANX N/A
- BHVN N/A
- EPS Growth
- JANX N/A
- BHVN N/A
- EPS
- JANX N/A
- BHVN N/A
- Revenue
- JANX $10,000,000.00
- BHVN N/A
- Revenue This Year
- JANX N/A
- BHVN N/A
- Revenue Next Year
- JANX $89.91
- BHVN $2,079.03
- P/E Ratio
- JANX N/A
- BHVN N/A
- Revenue Growth
- JANX N/A
- BHVN N/A
- 52 Week Low
- JANX $21.73
- BHVN $7.48
- 52 Week High
- JANX $71.71
- BHVN $50.40
- Technical
- Relative Strength Index (RSI)
- JANX 58.15
- BHVN 29.46
- Support Level
- JANX $26.96
- BHVN $7.48
- Resistance Level
- JANX $29.53
- BHVN $8.77
- Average True Range (ATR)
- JANX 2.10
- BHVN 1.12
- MACD
- JANX 0.00
- BHVN -0.71
- Stochastic Oscillator
- JANX 67.36
- BHVN 7.26
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.